Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifostine IV vs SC for Prevention of Xerostomia in Head and Neck Cancer
NCT00158691Phase 3Completed
- Sponsor
- GORTEC
- Start
- Mar 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of amifostine in xerostomia (2 arms), sponsored by GORTEC. Primary endpoint: Late xerostomia rate. Started Mar 2001; status: completed.
02
Drugs
amifostine
03
Conditions
xerostomia
Beyond the preview
Go deeper on NCT00158691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00158691.